

Tamir Biotechnology, Inc.  
Form NT 10-Q  
March 18, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 12b-25

NOTIFICATION OF LATE FILING

(CHECK ONE):  Form 10-K  Form 20-F  Form 11-Kx  Form 10-Q  Form N-SAR

For Period January 31, 2011  
Ended:

- Transition Report on Form 10-K
  - Transition Report on Form 20-F
  - Transition Report on Form 11-K
  - Transition Report on Form 10-Q
  - Transition Report on Form N-SAR
- For the Transaction Period Ended:

READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.  
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED  
ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Tamir Biotechnology, Inc.  
Full Name of Registrant

N/A  
Former Name if Applicable

11 Deer Park Drive, Suite 204  
Address of Principal Executive Office (Street and Number)

Monmouth Junction, NJ 08852  
City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

Edgar Filing: Tamir Biotechnology, Inc. - Form NT 10-Q

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K, Form N-SAR, Form N-SAR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

Tamir Biotechnology, Inc. (the "Company") is unable to file its Quarterly Report on Form 10-Q for the quarter ended January 31, 2011 (the "January Form 10-Q") without unreasonable effort or expense because of the recent operational changes implemented by the Company due to its limited resources, the Company has not completed its review for the quarter ended January 31, 2011 to ensure the disclosures to be contained in the January Form 10-Q are accurate. The Company is currently in the process of reviewing certain financial and other information necessary to finalize the January Form 10-Q and the consolidated financial statements included therein. The Company and its outside advisors, including its independent accountants, are working to complete the January Form 10-Q as expeditiously as possible. The Company expects to file the January Form 10-Q on or before the fifth calendar day following the prescribed due date.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

|               |             |                    |
|---------------|-------------|--------------------|
| Charles Muniz | (732)       | 823-1003           |
| (Name)        | (Area Code) | (Telephone Number) |

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the

results cannot be made.

Tamir Biotechnology, Inc.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 18, 2011

By: /s/ Charles Muniz  
Charles Muniz  
President, Chief Executive Officer  
and Chief Financial Officer